Detected ·
T-Therapeutics Ltd
$133MSeries B
T-Therapeutics Ltd closed an oversubscribed $133 million Series B financing to advance its TCR-CD3 bispecific therapies for cancer and autoimmune disease into clinical proof-of-concept.
- Website
- —
- linkedin.com/company/93112302
- Amount
- $133 000 000 USD
- Stage
- Series B
- Event
- Funding round
- Detected
- 2026-11-06 00:02:10 UTC
- Signal ID
- 87055bec-2367-4b51-b216-64da1626e3a3
As the API returns it
{
"id": "87055bec-2367-4b51-b216-64da1626e3a3",
"created_at": "2026-11-06T00:02:10.481445Z",
"company_name": "T-Therapeutics Ltd",
"company_website_url": null,
"company_linkedin_url": "https://www.linkedin.com/company/93112302",
"event_type": "funding",
"funding_amount": 133000000,
"funding_currency": "USD",
"funding_stage": "series_b",
"message": "*T-Therapeutics Ltd closed an oversubscribed $133 million Series B financing to advance its TCR-CD3 bispecific therapies for cancer and autoimmune disease into clinical proof-of-concept.*"
}